rethinkTHC Search
Menu
Study breakdown

THC May Protect Brain Cells From HIV-Related Aging and Inflammation

PreclinicalPreliminary evidence
The takeaway

In a primate model of HIV, THC treatment reversed virus-induced premature aging of brain support cells (astrocytes) and reduced inflammatory signaling, suggesting cannabinoids could help protect the brain during chronic HIV infection.

HIV researchers, neuroinflammation specialists, and people living with HIV interested in cannabinoid-based neuroprotection.

What the researchers found

THC treatment protected astrocytes from SIV-induced senescence (premature cellular aging), promoted recovery from Tat protein-induced damage, enhanced neuroprotective cell morphology, and significantly reduced inflammatory cytokines TNF-α, IL-6, and IL-1β in a dose-dependent manner.

Why it matters

Despite effective antiretroviral therapy, chronic brain inflammation remains a major problem for people living with HIV. This study suggests THC could address this unmet need by reversing cellular aging and reducing inflammation in brain support cells.

The numbers in context

THC significantly reduced TNF-α, IL-6, and IL-1β secretion in a dose-dependent manner. THC promoted glial process elongation and morphological complexity indicative of a neuroprotective phenotype.

How the study worked

Researchers used primary mixed glial cultures from rhesus macaques, assessing cell integrity via real-time impedance monitoring (xCELLigence), morphology via phase-contrast microscopy, and cytokine levels via multiplex immunoassays after THC and HIV Tat protein exposure.

What this study cannot tell us

Preclinical study using primate cell cultures — results may not directly translate to humans. The study examined THC in isolation, not as part of whole-plant cannabis. Dose-response relationships in cell culture may differ from clinical dosing.

How to read the evidence

Preclinical study using primate-derived cell cultures with multiple validated assessment methods, but no human clinical data.

When this study was published

Published 2025.

The bigger picture

About half of people living with HIV experience some form of neurocognitive impairment despite effective antiretroviral therapy. If THC's neuroprotective effects translate from primate models to humans, it could offer an adjunct therapeutic strategy for HIV-associated brain injury.

Questions still open

  • Would THC show similar neuroprotective effects in human clinical trials of people living with HIV? Could cannabinoid therapy complement antiretroviral treatment for neurocognitive symptoms? What is the optimal dosing window?

Common questions

Should people with HIV use THC for brain protection?
This is early preclinical research using cell cultures. While promising, it has not been tested in human clinical trials. People living with HIV should discuss any cannabis use with their healthcare provider.
Why are astrocytes important in HIV brain disease?
Astrocytes are the most abundant brain support cells. When HIV causes them to age prematurely (senesce), they release inflammatory signals that damage surrounding neurons, contributing to cognitive decline.

Read the original research

THC reverses SIV-induced senescence in astrocytes: possible compensatory mechanism against HIV associated brain injury?

Frontiers in cellular neuroscience, 19, 1642917

Citation

Van Zandt, Alison R; Horn, Miranda D; Peterson, Tiffany A; Dickinson, Sarah Y; Frost, Elise M; MacLean, Andrew G. (2025). THC reverses SIV-induced senescence in astrocytes: possible compensatory mechanism against HIV associated brain injury?. Frontiers in cellular neuroscience, 19, 1642917. https://doi.org/10.3389/fncel.2025.1642917

Explore the wider topic